Cough syrup gives clue to breast cancer drug dose

Cough medicine An active ingredient of cough syrup is broken down in the same way as Tamoxifen

Related Stories

Giving breast cancer patients cough syrup might tell doctors how well they will respond to a vital drug.

Women often respond differently to Tamoxifen, which can mean they need a higher dose to get the same effect.

Researchers from the Erasmus Medical Centre in Rotterdam noticed the body deals with the active ingredient of cough syrup the same way - offering an easier way to make this calculation.

Charity Breakthrough Breast Cancer said it might cut side-effects for women.

Tamoxifen has helped improve UK breast cancer survival rates over the past two decades.

It works by blocking the effects of the female sex hormone oestrogen, which can stimulate growth in some tumours.

However, to work properly, the drug needs to be broken down, or metabolised, and some women appear better able to do this than others.

There is currently no easy way to tell in advance which women will be "good metabolisers" and which bad.

The Dutch researchers believe that the drug dextromethorphan, a drug which suppresses coughing, and often the active ingredient of cough syrup, could help.

It is broken down in exactly the same way as tamoxifen, and, is relatively harmless in comparison with the powerful anti-cancer drug.

Start Quote

This kind of work could help us to improve a woman's chance of successful breast cancer treatment.”

End Quote Caitlin Palframan Breakthrough Breast Cancer
Small doses

They presented their work at a cancer treatment congress in Berlin.

Anne-Joy de Graan, who led the project, gave breast cancer patients a small dose of cough syrup before taking their Tamoxifen pills two hours later.

Blood samples were taken to see if the processing of the cough syrup drug matched that of the Tamoxifen.

The results showed that levels of the cough drug accurately predicted levels of the chemicals produced when tamoxifen is broken down.

One patient was taking an anti-depressant known to interfere with tamoxifen metabolism, and a corresponding effect was spotted in the dextromethorphan levels.

Anne-Joy de Graan said: "Tamoxifen is prescribed to women for as much as five years, so it is highly important to know beforehand if the therapy is going to be effective.

"When it is known that a woman metabolises tamoxifen poorly, a switch in drugs or an increase in dose can be considered."

She now plans to refine the test and study it in a larger group of patients.

Caitlin Palframan, from Breakthrough Breast Cancer said, that while it was early research, predicting a woman's response to tamoxifen was "an important question".

She said: "This kind of work could help us to improve a woman's chance of successful breast cancer treatment and spare her unnecessary side effects by giving her the right drugs at the right dose for her."

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More Health stories



  • chocolate cake and strawberriesTrick your tongue

    Would this dessert taste different on a black plate?

  • Duke and Duchess of Cambridge and Prince George leaving New Zealand'Great ambassadors'

    How New Zealand reacted to William, Kate - and George

  • Major Power Failure ident on BBC2Going live

    Why BBC Two's launch was not all right on the night

  • Front display of radio Strange echoes

    The mysterious 'numbers stations' left over from the Cold War era

  • A letter from a Somali refugee to a Syrian child'Be a star'

    Children's uplifting letters of hope to homeless Syrians

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.